In fact, Piccio et al. suggested that the plasma expression of SELPLG and SELP can be used as potential biomarkers for evaluating the magnitude of platelet activation in a wide range of pathogenic conditions, including AF, rheumatic mitral stenosis, and ischemic heart disorder [10–13]. This evidence concerns the gene SELP and atrial fibrillation.